Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Clazakizumab by CSL for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD): Likelihood of Approval
Clazakizumab is under clinical development by CSL and currently in Phase III for End-Stage Kidney Disease (End-Stage Renal Disease or...
CSL-040 by CSL for Transplant Rejection: Likelihood of Approval
CSL-040 is under clinical development by CSL and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I...
Garadacimab by CSL for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase...
CSL-889 by CSL for Sickle Cell Disease: Likelihood of Approval
CSL-889 is under clinical development by CSL and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase...
Influenza [types A and B] (quadrivalent) vaccine by CSL for Unspecified Influenza Virus Infections: Likelihood of Approval
Influenza [types A and B] (quadrivalent) vaccine is under clinical development by CSL and currently in Phase III for Unspecified...
Immune globulin (human) by CSL for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Immune globulin (human) is under clinical development by CSL and currently in Phase III for Chronic Lymphocytic Leukemia (CLL). According...
Immune globulin (human) by CSL for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
Immune globulin (human) is under clinical development by CSL and currently in Phase III for Post-Acute Sequelae of COVID 2019...
Clazakizumab by CSL for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Clazakizumab is under clinical development by CSL and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Anumigilimab by CSL for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Anumigilimab is under clinical development by CSL and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Anumigilimab by CSL for Sickle Cell Disease: Likelihood of Approval
Anumigilimab is under clinical development by CSL and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase...
Garadacimab by CSL for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase...
Immune globulin (human) by CSL for Traumatic Spinal Cord Injury: Likelihood of Approval
Immune globulin (human) is under clinical development by CSL and currently in Phase I for Traumatic Spinal Cord Injury. According...
Garadacimab by CSL for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Pre-Registration for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)....
Trabikibart by CSL for Allergic Asthma: Likelihood of Approval
Trabikibart is under clinical development by CSL and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I...
CSL-311 by CSL for Allergic Asthma: Likelihood of Approval
CSL-311 is under clinical development by CSL and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I...